Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Vyvanse lisdexamphetamine: Phase III data

In a double-blind Phase III trial in 414 adults, 30, 50 and 70 mg doses of

Read the full 165 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE